Waverley Weighs Its Options With High Costs, Thin Margins
Small Molecule Oncology Specialist Battered By Competition
Executive Summary
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
You may also be interested in...
Alimta ANDA Products Hit Double Digits With Several Launches
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
Waverley Lists In Frankfurt
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
Celltrion Makes Tocilizumab Progress With Positive Data At EULAR 2023
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).